Skip to Content
Not all colorectal cancer treatments are the same. Find out more >

Venetoclax Pregnancy and Breastfeeding Warnings

Venetoclax is also known as: Venclexta

Venetoclax Pregnancy Warnings

Animal studies have revealed fetotoxicity (increased post-implantation loss and decreased fetal body weight) at exposures approximately 1.2 times the human clinical exposure based on AUC at the recommended human dose (RHD) of 400 mg daily; however, no teratogenicity was observed. Data from animal studies suggest human male fertility may be compromised based on testicular toxicity (germ cell loss) observed at exposures as low as 0.5 times the human AUC exposure at the RHD. No effects have been observed on estrus cycles, mating, fertility, corpora lutea, uterine implants, or live embryos per litter at dosages up to 600 mg/kg/day. There are no controlled data in human pregnancy. US FDA pregnancy category Not Assigned: The US FDA has amended the pregnancy labeling rule for prescription drug products to require labeling that includes a summary of risk, a discussion of the data supporting that summary, and relevant information to help health care providers make prescribing decisions and counsel women about the use of drugs during pregnancy. Pregnancy categories A, B, C, D and X are being phased out.

This drug may cause fetal harm based on its mechanism of action and findings in animals. US FDA pregnancy category: Not Assigned Comments: -Females of reproductive potential should undergo pregnancy testing before treatment initiation, and be advised to avoid pregnancy and use effective contraception during treatment and for at least 30 days after the last dose. -Males of reproductive potential should be advised to consider sperm banking due to the fertility problems this drug may cause in men.

See references

Venetoclax Breastfeeding Warnings

Breastfeeding should be discontinued during use of this drug. Excreted into human milk: Data not available. Excreted into animal milk: Data not available. Comments: The effects in the nursing infant and on milk production are unknown.

See references

References for pregnancy information

  1. "Product Information. Venclexta (venetoclax)." AbbVie US LLC, North Chicago, IL.

References for breastfeeding information

  1. "Product Information. Venclexta (venetoclax)." AbbVie US LLC, North Chicago, IL.

See Also...

Disclaimer: Every effort has been made to ensure that the information provided by Cerner Multum, Wolters Kluwer Health and Drugs.com is accurate, up-to-date and complete, but no guarantee is made to that effect. In addition, the drug information contained herein may be time sensitive and should not be utilized as a reference resource beyond the date hereof. This material does not endorse drugs, diagnose patients, or recommend therapy. This drug information is a reference resource designed as supplement to, and not a substitute for, the expertise, skill , knowledge, and judgement of healthcare practitioners in patient care. The absence of a warning for a given drug or combination thereof in no way should be construed to indicate that the drug or combination is safe, effective, or appropriate for any given patient. Multum Information Services, Inc. does not assume any responsibility for any aspect of healthcare administered with the aid of information Multum provides. Copyright 2000-2008 Multum Information Services, Inc. The information contained herein is not intended to cover all possible uses, directions, precautions, warnings, drug interactions, allergic reactions, or adverse effects. If you have questions about the drugs you are taking, check with your doctor, nurse, or pharmacist.

Hide